CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $10.35M, lower than 95% of all stocks globally
- PositionOperating margin is -25949.7%, lower than 95% of its Biotechnology peers (median -24.1%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.83BUSDvs all stocks (USD)
Revenue (TTM)
10.35MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.70xvs all stocks
52-Week Change
236.61%vs all stocks
Market Capitalization
3.83BUSDvs all stocks (USD)
Enterprise Value
2.95BUSDvs all stocks (USD)
Forward P/E
-10.67xvs Biotechnology peers
Price to Book (MRQ)
4.29xvs Biotechnology peers
Enterprise to Revenue
284.84xvs Biotechnology peers
Enterprise to EBITDA
-9.56xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-22.88%vs Biotechnology peers
Return on Equity (TTM)
-36.77%vs Biotechnology peers
Revenue (TTM)
10.35MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0570USDUpdated Sep 28, 2026Quarterly Revenue Growth
-48.30%vs Biotechnology peers
Gross Profit (TTM)
-258.50MUSDvs all stocks (USD)
EBITDA (TTM)
-308.22MUSDvs all stocks (USD)
Net Income (TTM)
-286.04MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-48.30%vs Biotechnology peers
Operating Cash Flow (TTM)
-212.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-119.24MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
15.36MUSDFY2025 · Dec 31, 2025Operating Income
-302.74MUSDvs all stocks (USD)
Pre-tax Income
-276.48MUSDFY2025 · Dec 31, 2025Net Income
-276.48MUSDFY2025 · Dec 31, 2025EBIT
-302.74MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-299.18MUSDFY2025 · Dec 31, 2025Research & Development
261.38MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
56.71MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
27.04MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-276.48MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-223.98MUSDFY2025 · Dec 31, 2025Free Cash Flow
-224.39MUSDDerived from operating cash flow minus capital expenditure. This filing charges 3.56M of depreciation against 410K of capital expenditure, and its own free-cash-flow line reads -235.87M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
85.35MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-276.48MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.56MUSDFY2025 · Dec 31, 2025Stock-based Compensation
62.42MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-13.48MUSDFY2025 · Dec 31, 2025Capital Expenditures
-410.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-122.97MUSDFY2025 · Dec 31, 2025Sale of Investments
316.18MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
192.80MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
218.53MSharesUpdated Sep 28, 2026Float Shares
145.48MSharesUpdated Sep 28, 2026Shares Short
44.49MSharesUpdated Sep 28, 2026Short Ratio
15.30daysvs all stocks
Short % of Shares Outstanding
23.64%vs all stocks
% Held by Insiders
1.61%vs all stocks
% Held by Institutions
110.93%vs all stocks
Total Cash (MRQ)
910.93MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.16USDUpdated Sep 28, 2026Total Debt (MRQ)
30.66MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0345xvs Biotechnology peers
Current Ratio (MRQ)
18.27xvs Biotechnology peers
Book Value per Share (MRQ)
4.07USDUpdated Sep 28, 2026Total Assets
621.33MUSDvs all stocks (USD)
Total Current Assets
578.28MUSDFY2025 · Dec 31, 2025Total Liabilities
54.27MUSDFY2025 · Dec 31, 2025Total Non-current Assets
43.05MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
28.69MUSDFY2025 · Dec 31, 2025Total Current Liabilities
25.58MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
84.02MUSDFY2025 · Dec 31, 2025Other Short-term Investments
470.50MUSDFY2025 · Dec 31, 2025Accounts Payable
7.71MUSDFY2025 · Dec 31, 2025Short-term Debt
3.77MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
463.00KUSDFY2025 · Dec 31, 2025Long-term Debt
28.69MUSDFY2025 · Dec 31, 2025Common Stock (Book)
168.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.01BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
567.06MUSDvs all stocks (USD)
52-Week Low
5.01USDUpdated Sep 28, 202652-Week High
21.27USDUpdated Sep 28, 202652-Week Change
236.61%vs all stocks
Beta
1.70xvs all stocks
50-Day MA
19.20USDUpdated Sep 28, 2026200-Day MA
13.75USDUpdated Sep 28, 2026Avg 10-Day Volume
3.85MSharesUpdated Sep 28, 2026Avg 30-Day Volume
3.20MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.56USDUpdated Sep 28, 2026Other Income / Expense
-776.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -25949.7%, lower than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: -259.497Industry median: -0.24Industry P5: -33.54Peers compared: 193
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $10.35M, lower than 95% of all stocks globallySignificant
Revenue (USD): 10,350,000Global P5: 33,357,653.812
Market cap is $3.83B, above the global median of $1.18BNotable
Market cap (USD): 3,828,404,293Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Catalyst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Duality Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Celcuity Inc.
Tier 1ProductionApproval-Gated PipelineRule
Amylyx Pharmaceuticals, Inc. Common Stock
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wockhardt Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Tiantan Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Grand Pharmaceutical and Healthcare Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Pulse Biosciences Inc.
2 interpretationsLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Iovance Biotherapeutics, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Absci Corporation
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity